Farnesyl diphosphate

Farnesyl diphosphate is a lipid of Prenol Lipids (PR) class. Farnesyl diphosphate is associated with abnormalities such as Dental caries and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Regulation, Process, Signal, Anabolism and inhibitors. Farnesyl diphosphate often locates in peroxisome, Cytoplasmic matrix, Plasma membrane, soluble and Mitochondria. The associated genes with Farnesyl diphosphate are HSD3B1 gene, ABRA gene, MATN1 gene, SEPSECS gene and MBD2 gene. The related lipids are Sterols, 22-hydroxycholesterol, dehydrosqualene, SK&F 104976 and 25-hydroxycholesterol.

Cross Reference

Introduction

To understand associated biological information of Farnesyl diphosphate, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Farnesyl diphosphate?

Farnesyl diphosphate is suspected in and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Farnesyl diphosphate

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Endometriosis D004715 29 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Liver Neoplasms, Experimental D008114 46 associated lipids
Protozoan Infections D011528 6 associated lipids
Osteosarcoma D012516 50 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Total 10

PubChem Associated disorders and diseases

What pathways are associated with Farnesyl diphosphate

Lipid pathways are not clear in current pathway databases. We organized associated pathways with Farnesyl diphosphate through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Farnesyl diphosphate?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Farnesyl diphosphate?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Farnesyl diphosphate?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Farnesyl diphosphate?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Farnesyl diphosphate?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Farnesyl diphosphate

Download all related citations
Per page 10 20 50 100 | Total 614
Authors Title Published Journal PubMed Link
Minutolo F et al. Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity. 2003 Farmaco pmid:14630239
Aharoni A et al. Terpenoid metabolism in wild-type and transgenic Arabidopsis plants. 2003 Plant Cell pmid:14630967
Deligeorgopoulou A and Allemann RK Evidence for differential folding of farnesyl pyrophosphate in the active site of aristolochene synthase: a single-point mutation converts aristolochene synthase into an (E)-beta-farnesene synthase. 2003 Biochemistry pmid:12820883
Kotsikorou E and Oldfield E A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. 2003 J. Med. Chem. pmid:12825934
Shiota Y et al. Effects of peroxisome proliferators gemfibrozil and clofibrate on syntheses of dolichol and cholesterol in rat liver. 2003 J. Biochem. pmid:12966067
Fukuchi J et al. Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. 2003 Steroids pmid:12957674
Deligeorgopoulou A et al. Stabilisation of eudesmane cation by tryptophan 334 during aristolochene synthase catalysis. 2003 Chem. Commun. (Camb.) pmid:13678181
Fairlamb IJ et al. Synthesis and antimicrobial evaluation of farnesyl diphosphate mimetics. 2003 Bioorg. Chem. pmid:12697170
Turek-Etienne TC et al. Biochemical and structural studies with prenyl diphosphate analogues provide insights into isoprenoid recognition by protein farnesyl transferase. 2003 Biochemistry pmid:12667062
Lannuzel M et al. From pure FPP to mixed FPP and CAAX competitive inhibitors of farnesyl protein transferase. 2003 Bioorg. Med. Chem. Lett. pmid:12668012
van Klink J et al. Biosynthesis of anthecotuloide, an irregular sesquiterpene lactone from Anthemis cotula L. (Asteraceae) via a non-farnesyl diphosphate route. 2003 Org. Biomol. Chem. pmid:12926279
Huang CF et al. Farnesyl pyrophosphate promotes and is essential for the binding of RACK1 with beta-tubulin. 2003 J. Exp. Zoolog. Part A Comp. Exp. Biol. pmid:12884273
Chang SY et al. Identification of the active conformation and the importance of length of the flexible loop 72-83 in regulating the conformational change of undecaprenyl pyrophosphate synthase. 2003 Biochemistry pmid:14661956
Kaneta S et al. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. 2003 Atherosclerosis pmid:14612203
Zhou Y et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. 2003 Science pmid:14615541
Huang KC et al. Statins induce suppressor of cytokine signaling-3 in macrophages. 2003 FEBS Lett. pmid:14644448
Pickett JS et al. Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand. 2003 J. Biol. Chem. pmid:14532266
Kovacs WJ and Krisans S Cholesterol biosynthesis and regulation: role of peroxisomes. 2003 Adv. Exp. Med. Biol. pmid:14713247
Song L Detection of farnesyl diphosphate accumulation in yeast ERG9 mutants. 2003 Anal. Biochem. pmid:12758256
Mau CJ et al. Protein farnesyltransferase inhibitors interfere with farnesyl diphosphate binding by rubber transferase. 2003 Eur. J. Biochem. pmid:14511375
Hümbelin M et al. Genetics of isoprenoid biosynthesis in Paracoccus zeaxanthinifaciens. 2002 Gene pmid:12384294
Blanco-Colio LM et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. 2002 Atherosclerosis pmid:11882313
Seo M and Koshiba T Complex regulation of ABA biosynthesis in plants. 2002 Trends Plant Sci. pmid:11804826
Tacer KF et al. Tissue-specific transcriptional regulation of the cholesterol biosynthetic pathway leads to accumulation of testis meiosis-activating sterol (T-MAS). 2002 J. Lipid Res. pmid:11792726
Kovacs WJ et al. Central role of peroxisomes in isoprenoid biosynthesis. 2002 Prog. Lipid Res. pmid:12121718
Sánchez De Cos Escuín J [New therapeutic targets and strategies in lung cancer]. 2002 Arch. Bronconeumol. pmid:12199921
Rawat DS and Gibbs RA Synthesis of 7-substituted farnesyl diphosphate analogues. 2002 Org. Lett. pmid:12201708
Vincent L et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. 2002 Arterioscler. Thromb. Vasc. Biol. pmid:11950701
Zhou C et al. Aromatic farnesyl diphosphate analogues: vinyl triflate-mediated synthesis and preliminary enzymatic evaluation. 2002 Bioorg. Med. Chem. Lett. pmid:11992789
Chehade KA et al. Photoaffinity analogues of farnesyl pyrophosphate transferable by protein farnesyl transferase. 2002 J. Am. Chem. Soc. pmid:12105898
Dursina B et al. Interaction of yeast Rab geranylgeranyl transferase with its protein and lipid substrates. 2002 Biochemistry pmid:12022885
Holstein SA et al. Isoprenoids influence expression of Ras and Ras-related proteins. 2002 Biochemistry pmid:12427032
Okamoto T et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. 2002 Biochem. Biophys. Res. Commun. pmid:12237136
Miki T et al. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. 2002 J. Med. Chem. pmid:12238936
Chen CH et al. Effects of prenyl pyrophosphates on the binding of S-Ras proteins with KSR. 2002 J. Exp. Zool. pmid:12410604
Ayral-Kaloustian S and Salaski EJ Protein farnesyltransferase inhibitors. 2002 Curr. Med. Chem. pmid:12733981
Calvert MJ et al. Germacrene A is a product of the aristolochene synthase-mediated conversion of farnesylpyrophosphate to aristolochene. 2002 J. Am. Chem. Soc. pmid:12296728
Chen AP et al. Synthesis and application of a fluorescent substrate analogue to study ligand interactions for undecaprenyl pyrophosphate synthase. 2002 J. Am. Chem. Soc. pmid:12487597
Spiteller D et al. Feeding of [5,5-2H(2)]-1-desoxy-D-xylulose and [4,4,6,6,6-2H(5)]-mevalolactone to a geosmin-producing Streptomyces sp. and Fossombronia pusilla. 2002 Phytochemistry pmid:12453575
Kalinowski L et al. Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis. 2002 J. Physiol. Pharmacol. pmid:12512694
Cheng Q et al. Geranylgeranyl pyrophosphate counteracts the cataractogenic effect of lovastatin on cultured rat lenses. 2002 Exp. Eye Res. pmid:12457872
Swiatkowska M et al. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity. 2002 Jpn. J. Pharmacol. pmid:12501010
Jarstfer MB et al. Recombinant squalene synthase. Synthesis of non-head-to-tail isoprenoids in the absence of NADPH. 2002 J. Am. Chem. Soc. pmid:12137536
Blagg BS et al. Recombinant squalene synthase. A mechanism for the rearrangement of presqualene diphosphate to squalene. 2002 J. Am. Chem. Soc. pmid:12137537
Wentzinger LF et al. Inhibition of squalene synthase and squalene epoxidase in tobacco cells triggers an up-regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase. 2002 Plant Physiol. pmid:12226513
Little DB and Croteau RB Alteration of product formation by directed mutagenesis and truncation of the multiple-product sesquiterpene synthases delta-selinene synthase and gamma-humulene synthase. 2002 Arch. Biochem. Biophys. pmid:12051690
Du Y and Wiemer DF Alpha-phosphono lactone analogues of farnesyl pyrophosphate: an asymmetric synthesis via ring-closing metathesis. 2002 J. Org. Chem. pmid:12153272
Pan JJ et al. Insight into the activation mechanism of Escherichia coli octaprenyl pyrophosphate synthase derived from pre-steady-state kinetic analysis. 2002 Biochim. Biophys. Acta pmid:11825609
Shaikenov TE et al. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase. 2001 Jan-Feb Oncol. Rep. pmid:11115593
Martin VJ et al. The in vivo synthesis of plant sesquiterpenes by Escherichia coli. 2001 Biotechnol. Bioeng. pmid:11745124